FOR IMMEDIATE RELEASE
- New portfolio adds combination peptide pens and intranasal delivery formats to Cellgenic’s peptide product line
- Delivery-format innovation, not a new peptide compound, is the core of the announcement
- Launch responds to international physician demand for more convenient peptide administration options
MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced a next-generation peptide delivery portfolio featuring combination peptide pens and intranasal delivery formats, developed in response to international physician and market demand for more convenient and diversified peptide administration options.
The new delivery formats expand how physicians in Cellgenic’s markets can offer peptide-based products within their practices, including applications in physician-directed optimization, longevity, and wellness contexts where legally appropriate.
Cellgenic said the innovation is centered on delivery-platform convenience and format diversification rather than new active compounds, and that the portfolio is intended to complement its existing peptide product line.
“Physicians have told us convenience and administration flexibility matter as much as the underlying formulation,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This portfolio gives Cellgenic’s physician network combination pen and intranasal options that fit more easily into their practices.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About Cellgenic
Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com
